vaccine trials Articles
-
A Bayesian design for phase I cancer therapeutic vaccine trials
Abstract Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not ...
-
Medical Advancements
Covid-19 is approaching its one-year mark in the United States. As cases are on the rise again, people all over the world are eager for a cure. In the past few days, Moderna and Pfizer have released some promising clinical trials of their Covid-19 vaccinations. While these are still in the trial phase, many remain hopeful that the end of this deadly pandemic is near. ...
-
Preliminary evidence of efficacy from an open label trial of a therapeutic AIDS vaccine derived from the blood of HIV-positive donors
Two earlier reported studies indicated the beneficial clinical effects of THIVAC, a therapeutic HIV vaccine derived from the blood of HIV-positive donors. However, in those studies no stringent statistical analysis to support the beneficial clinical outcome was attempted. This report retrospectively analyses the effect of the therapy on the CD4 counts in 272 treated individuals who had at least ...
-
Safety and immunogenicity of bivalent inactivated vaccine against haemorrhagic fever with renal syndrome in a phase II trial on healthy Chinese volunteers
We have developed a cell culture-derived, inactivated bivalent vaccine against both Haemorrhagic Fever with Renal Syndrome (HFRS) viruses 84 Fli (type I) and L99 (type II). This purified vaccine was tested in the clinical phase I/II trial in healthy non-infected adults in China. About 518 volunteers in Southern region and 650 volunteers from the Northern region of China were vaccinated. ...
-
Rational Vaccines Announces a Clinical Trial to Determine Baseline Characteristics of Patients Diagnosed With Recurrent Symptomatic Herpes Simplex Type 2 (HSV-2) Virus
Study to be conducted at two leading research institutions in the U.K. Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the ...
-
The Major Breakthrough That Completely Stopped This Woman`s Painful Genital Herpes Outbreaks
In the span of seven days, Mel Smith left her verbally abusive boyfriend, moved out of their house with her 13-year-old son, and found out that she had contracted genital herpes. “I didn’t know what it was. I didn’t know what to do,” she says, remembering the time five years ago when her vagina itched so badly she couldn’t wear underwear. Her diagnosis? Herpes ...
-
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine
MADISON, Wis.–(BUSINESS WIRE)–An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and testing of a unique vaccine against COVID-19 called CoroFlu. UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccineTweet this CoroFlu will build on the ...
By FluGen, Inc.
-
Preventive cancer vaccine based on neoantigens gets put to the test
Studying the vaccine in dogs could provide insight into its effectiveness in people What if someone told you that a vaccine shot could prevent you from getting multiple types of cancer—ones as different from each other as breast cancer and lymphoma? Stephen A. Johnston, cofounder of the health-care start-up Calviri and a scientist at Arizona State University’s Biodesign Institute, ...
By Calviri
-
Bioprocess Automation, Remote Monitoring, and Real-Time Data Capture Underpin Operation Warp Speed’s Push for a COVID-19 Vaccine
Life science companies spanning the globe are striving to quickly develop and commercialize COVID-19 therapeutics and grab the brass ring of a viable, effective, and safe SARS-CoV-2 vaccine. In the United States, pharmaceutical and biotech companies, as well as Contract Development and Manufacturing Organizations (CDMOs), from coast-to-coast are racing to complete clinical trials and forge ...
By Lab Owl
-
Editorial: Research, Development and Clinical Trials for Peptide-Based Vaccines
From the eradication of smallpox through to the global response to the COVID-19 pandemic, vaccines have been a cornerstone in the fight against infectious diseases in humans and livestock since the 18th century. Although vaccines against COVID-19 are unlikely to eradicate the disease in the way that the smallpox vaccine did, they have proved very effective in preventing death and hospitalisation, ...
-
HIV-1 subtype C vaccine: waiting in wings for the human trials
India has more than 5 million people infected with HIV-1 and this number is likely to increase in coming years. It is estimated that by the turn of this decade more than 10 million people would have been infected with this virus. More than 90% of these infections are due to subtype C. Therefore, it is imperative that a vaccine be developed based on local circulating subtype and tested for ...
-
Micron developing microneedle technology for self-administration of vaccines and therapeutics
Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics. “While microneedle technology is not new, our company represents the evolution of the technology over many years,” Steven Damon, CEO, says in an interview with BioTuesdays.com. “We’re developing an innovative ...
-
FluGen Initiates NIH-Funded Trial of M2SR Flu Vaccine; First Study in Adults Up to Age 85
Study will measure immune responses to matched and drifted virus strains in older adults, a population that is most vulnerable to mortality from flu – Topline data expected in 1H 2022 – MADISON, Wis., May 25, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the initiation of the ...
By FluGen, Inc.
-
RVx201 Herpes Vaccine
RVx201 Herpes Vaccine Description 2022 RVx201 is a first-in-human herpes simplex virus type 2 (HSV-2) live-attenuated therapeutic vaccine modified to be interferon sensitive that destroys the ability of the virus to inhibit immune responses. Produced by Rational Vaccines, Inc., the technology is based on the pioneering research of the late Dr. William Halford, who dedicated over 25 years to ...
-
The race to a vaccine - unintended consequences?
A gold rush is on to find a vaccine for COVID-19. According to the World Health Association (WHO) in early May, there are more than 100 projects around the world centered on the development of a vaccine for the coronavirus. Eight candidate vaccines are already being tested in people in clinical trials. Once an effective vaccine (or vaccines) has been identified, it will need to be produced ...
By Vistex Inc
-
Nipah virus glycoprotein structure suggests therapeutic strategies
Recent molecular discoveries have provided new details on how Nipah and Hendra viruses attack cells, and the immune responses that fight back against this attack. The findings point to a multi-pronged strategy for preventing and treating these deadly diseases. The study was published in Science recently. Both Nipah virus and Hendra virus are carried by indigenous bats in some parts of the ...
-
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal ...
By FluGen, Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you